Managing Toxicities with Sorafenib in HCC - Targeted Oncology

Managing Toxicities with Sorafenib in HCC  Targeted Oncology

Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immun...

Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma  Nature

18F-FDG and 18F-Fluorocholine PET as Prognostic Biomarkers in Patients with Advanced Hepatocellul...

18F-FDG and 18F-Fluorocholine PET as Prognostic Biomarkers in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Prospective Multicenter Study  Journal of Nuclear Medicine

Fluorinated Proteolysis Targeting Chimeras-Sorafenib Nanoassembly for Epigenetic Remodeling to Co...

Fluorinated Proteolysis Targeting Chimeras-Sorafenib Nanoassembly for Epigenetic Remodeling to Combat Multi-Pathway Drug Resistance in Hepatocellular Carcinoma  ACS Publications

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellu...

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study  The Lancet

Frontline Sorafenib Shows Promising Outcomes in Metastatic Uveal Melanoma - CancerNetwork

Frontline Sorafenib Shows Promising Outcomes in Metastatic Uveal Melanoma  CancerNetwork

From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma ...

From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma  ASCO Daily News

Targeting metabolic vulnerabilities: REV-ERB agonist SR9009 potentiates sorafenib efficacy in liv...

Targeting metabolic vulnerabilities: REV-ERB agonist SR9009 potentiates sorafenib efficacy in liver cancer  Nature

Fluorinated Proteolysis Targeting Chimeras-Sorafenib Nanoassembly for Epigenetic Remodeling to Co...

Fluorinated Proteolysis Targeting Chimeras-Sorafenib Nanoassembly for Epigenetic Remodeling to Combat Multi-Pathway Drug Resistance in Hepatocellular Carcinoma  ACS Publications

Synergistic antitumor activity of sorafenib and the NUPR1 inhibitor LZX-2-73 in multiple cancer m...

Synergistic antitumor activity of sorafenib and the NUPR1 inhibitor LZX-2-73 in multiple cancer models  Nature

Y resin microspheres for the treatment of uveal melanoma with liver metastasis: a phase I trial -...

Y resin microspheres for the treatment of uveal melanoma with liver metastasis: a phase I trial  Nature

CAPRIN1-mediated sequestration of NCOA4 mRNA into stress granules drives sorafenib resistance in ...

CAPRIN1-mediated sequestration of NCOA4 mRNA into stress granules drives sorafenib resistance in hepatocellular carcinoma  Nature

AI fragmentation-based optimization of Sorafenib derivatives targeting VEGFR2 for angiogenesis-re...

AI fragmentation-based optimization of Sorafenib derivatives targeting VEGFR2 for angiogenesis-related pathologies: a structure-based in-silico study  Nature

MOF enhances the sensitivity and selectivity of sorafenib as an anticancer drug against hepatocel...

MOF enhances the sensitivity and selectivity of sorafenib as an anticancer drug against hepatocellular carcinoma and colorectal cancer in vitro  Nature

ZEB1 stratifies the response to Sorafenib and Mdivi-1 combination therapy in hepatocellular carci...

ZEB1 stratifies the response to Sorafenib and Mdivi-1 combination therapy in hepatocellular carcinoma  Nature

LINC00162 silencing enhances sorafenib sensitivity and inhibits thyroid cancer cells progression ...

LINC00162 silencing enhances sorafenib sensitivity and inhibits thyroid cancer cells progression through modulation of MAPK signaling and apoptosis  Nature

SLC25A39 regulates Hedgehog signaling to promote tumor progression and sorafenib resistance in he...

SLC25A39 regulates Hedgehog signaling to promote tumor progression and sorafenib resistance in hepatocellular carcinoma  Nature

D-lactate and glycerol as potential biomarkers of sorafenib activity in hepatocellular carcinoma ...

D-lactate and glycerol as potential biomarkers of sorafenib activity in hepatocellular carcinoma  Nature

Matrix stiffness regulates glucose-6-phosphate dehydrogenase expression to mediate sorafenib resi...

Matrix stiffness regulates glucose-6-phosphate dehydrogenase expression to mediate sorafenib resistance in hepatocellular carcinoma through the ITGB1-PI3K/AKT pathway  Nature

Immune system development-related signature predicts prognosis and sorafenib-treatment resistance...

Immune system development-related signature predicts prognosis and sorafenib-treatment resistance of hepatocellular carcinoma by intergrating machine learning and single-cell analyses  Nature

Final Results of CARES-310 Study: Camrelizumab + Rivoceranib vs Sorafenib in Unresectable HCC - O...

Final Results of CARES-310 Study: Camrelizumab + Rivoceranib vs Sorafenib in Unresectable HCC  Oncodaily

Complete Radiological Response to Sorafenib in Aggressive Intra-Abdominal Desmoid Tumor A Case Re...

Complete Radiological Response to Sorafenib in Aggressive Intra-Abdominal Desmoid Tumor A Case Report  SCIRP Open Access

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer - 2 Minu...

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer  2 Minute Medicine

Targeting MCM10 disrupts cancer stemness and counteracts sorafenib resistance in hepatocellular c...

Targeting MCM10 disrupts cancer stemness and counteracts sorafenib resistance in hepatocellular carcinoma  Nature

LEVIATHAN Study Results: Lenvatinib vs Sorafenib as 2L Treatment for Hepatocellular Carcinoma - O...

LEVIATHAN Study Results: Lenvatinib vs Sorafenib as 2L Treatment for Hepatocellular Carcinoma  Oncodaily

Frontline Nivolumab/Ipilimumab Delivers Long-Term Efficacy in Unresectable HCC - OncLive

Frontline Nivolumab/Ipilimumab Delivers Long-Term Efficacy in Unresectable HCC  OncLive

Cost-effectiveness analysis of toripalimab plus bevacizumab versus sorafenib as first-line treatm...

Cost-effectiveness analysis of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China  Frontiers

Sorafenib Market Research Report 2026-2030 - Increasing Cancer Incidence Spurs Sorafenib Market E...

Sorafenib Market Research Report 2026-2030 - Increasing Cancer Incidence Spurs Sorafenib Market Expansion  GlobeNewswire

FDA Accepts NDA for Rivoceranib and Camrelizumab in 1L Unresectable HCC - CancerNetwork

FDA Accepts NDA for Rivoceranib and Camrelizumab in 1L Unresectable HCC  CancerNetwork

Inhibition of Wnt/β-catenin increases anti-tumor activity by synergizing with sorafenib in hepato...

Inhibition of Wnt/β-catenin increases anti-tumor activity by synergizing with sorafenib in hepatocellular carcinoma  Nature

Paris court invalidates crucial claim of Bayer’s sorafenib patent - JUVE Patent

Paris court invalidates crucial claim of Bayer’s sorafenib patent  JUVE Patent

Cost-effectiveness analysis of toripalimab plus bevacizumab versus sorafenib as first-line treatm...

Cost-effectiveness analysis of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China  Frontiers

Targeting SIX2 as a novel sensitization strategy of sorafenib treatment on advanced hepatocellula...

Targeting SIX2 as a novel sensitization strategy of sorafenib treatment on advanced hepatocellular carcinoma through modulating METTL9-SLC7A11 axis  Nature

Analyzing Nivolumab and Ipilimumab as HCC Therapy - Targeted Oncology

Analyzing Nivolumab and Ipilimumab as HCC Therapy  Targeted Oncology

Anlotinib/Penpulimab Enhances Survival vs Sorafenib in Unresectable HCC - CancerNetwork

Anlotinib/Penpulimab Enhances Survival vs Sorafenib in Unresectable HCC  CancerNetwork

CheckMate 9DW at ASCO GI 2026: Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line...

CheckMate 9DW at ASCO GI 2026: Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma  Oncodaily

Sorafenib-to-regorafenib sequence-induced atherosclerotic cardiovascular disease: a novel case re...

Sorafenib-to-regorafenib sequence-induced atherosclerotic cardiovascular disease: a novel case report  Frontiers

Application of Helmholtz Coils and superparamagnetic nanocarrier in localized inhibition of cance...

Application of Helmholtz Coils and superparamagnetic nanocarrier in localized inhibition of cancer cell migration and invasion  ScienceDirect.com

The prognostic value of selected indices combination in hepatocellular carcinoma patients treated...

The prognostic value of selected indices combination in hepatocellular carcinoma patients treated with sorafenib  Via Medica Journals

PIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocell...

PIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocellular Carcinoma  Wiley

SHBs Mitigates Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma via Activation of RAF1/MEK...

SHBs Mitigates Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma via Activation of RAF1/MEK/ERK Signaling Pathway  Wiley Online Library

Nivolumab/Ipilimumab Maintains OS, ORR Benefits in Chinese Patients With Unresectable HCC - OncLive

Nivolumab/Ipilimumab Maintains OS, ORR Benefits in Chinese Patients With Unresectable HCC  OncLive

Anlotinib Plus Penpulimab in First-Line Treatment of Unresectable Hepatocellular Carcinoma - The ...

Anlotinib Plus Penpulimab in First-Line Treatment of Unresectable Hepatocellular Carcinoma  The ASCO Post

Clinical breakthrough: Five-year survival in patients with unresectable hepatocellular carcinoma ...

Clinical breakthrough: Five-year survival in patients with unresectable hepatocellular carcinoma sets an unprecedented milestone poised to reshape clinical practice  EurekAlert!

Autophagy modulation attenuates sorafenib resistance in HCC induced in rats - Nature

Autophagy modulation attenuates sorafenib resistance in HCC induced in rats  Nature

Oleanolic acid restores drug sensitivity in sorafenib-resistant hepatocellular carcinoma: evidenc...

Oleanolic acid restores drug sensitivity in sorafenib-resistant hepatocellular carcinoma: evidence from in vitro and in vivo studies  EurekAlert!

Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma i...

Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy  Nature

Sorafenib for Advanced and Refractory Desmoid Tumors - The New England Journal of Medicine

Sorafenib for Advanced and Refractory Desmoid Tumors  The New England Journal of Medicine

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable...

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial  The Lancet

Medicine International - Spandidos Publications

Medicine International  Spandidos Publications

Sameer Rastogi Shared Early Results from SORASTOP Trial on Discontinuing Sorafenib in Desmoid Tum...

Sameer Rastogi Shared Early Results from SORASTOP Trial on Discontinuing Sorafenib in Desmoid Tumors  Oncodaily

Mechanism of sorafenib resistance associated with ferroptosis in HCC - Frontiers

Mechanism of sorafenib resistance associated with ferroptosis in HCC  Frontiers

Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors - Nature

Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors  Nature

CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1 - Nature

CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1  Nature

New knowledge of the mechanisms of sorafenib resistance in liver cancer - Nature

New knowledge of the mechanisms of sorafenib resistance in liver cancer  Nature

MCM2 promotes the stemness and sorafenib resistance of hepatocellular carcinoma cells via hippo s...

MCM2 promotes the stemness and sorafenib resistance of hepatocellular carcinoma cells via hippo signaling  Nature

Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-...

Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma  Nature

3-hydroxyanthranic acid increases the sensitivity of hepatocellular carcinoma to sorafenib by dec...

3-hydroxyanthranic acid increases the sensitivity of hepatocellular carcinoma to sorafenib by decreasing tumor cell stemness  Nature

Oral sorafenib-loaded microemulsion for breast cancer: evidences from the in-vitro evaluations an...

Oral sorafenib-loaded microemulsion for breast cancer: evidences from the in-vitro evaluations and pharmacokinetic studies  Nature

Pifithrin-μ sensitizes mTOR-activated liver cancer to sorafenib treatment - Nature

Pifithrin-μ sensitizes mTOR-activated liver cancer to sorafenib treatment  Nature

UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeosta...

UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma  Nature

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular ...

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial  The Lancet

Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneo...

Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneous Tumors  Frontiers

TRIM21 mediates the synergistic effect of Olaparib and Sorafenib by degrading BRCA1 through ubiqu...

TRIM21 mediates the synergistic effect of Olaparib and Sorafenib by degrading BRCA1 through ubiquitination in TNBC  Nature

GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition o...

GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis  Nature

RCN1 induces sorafenib resistance and malignancy in hepatocellular carcinoma by activating c-MYC ...

RCN1 induces sorafenib resistance and malignancy in hepatocellular carcinoma by activating c-MYC signaling via the IRE1α–XBP1s pathway  Nature

Sorafenib inhibits LPS-induced inflammation by regulating Lyn-MAPK-NF-kB/AP-1 pathway and TLR4 ex...

Sorafenib inhibits LPS-induced inflammation by regulating Lyn-MAPK-NF-kB/AP-1 pathway and TLR4 expression  Nature

Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after so...

Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure  Nature

TLR3 activation enhances antitumor effects of sorafenib in hepatocellular carcinoma by activating...

TLR3 activation enhances antitumor effects of sorafenib in hepatocellular carcinoma by activating NK cell functions through ERK and NF-κB pathways | Scientific Reports  Nature

Tribbles Pseudokinase 3 Converts Sorafenib Therapy to Neutrophil-Mediated Lung Metastasis in Hepa...

Tribbles Pseudokinase 3 Converts Sorafenib Therapy to Neutrophil-Mediated Lung Metastasis in Hepatocellular Carcinoma  Wiley

Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FL...

Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial  The Lancet

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312...

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study  The Lancet

Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and acti...

Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition  PNAS

MCL1 inhibition: a promising approach to augment the efficacy of sorafenib in NSCLC through ferro...

MCL1 inhibition: a promising approach to augment the efficacy of sorafenib in NSCLC through ferroptosis induction  Nature

Hypoxia-induced DTL promotes the proliferation, metastasis, and sorafenib resistance of hepatocel...

Hypoxia-induced DTL promotes the proliferation, metastasis, and sorafenib resistance of hepatocellular carcinoma through ubiquitin-mediated degradation of SLTM and subsequent Notch pathway activation  Nature

SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glut...

SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase  Nature

A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous s...

A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia  Wiley

Sorafenib in Advanced Hepatocellular Carcinoma - The New England Journal of Medicine

Sorafenib in Advanced Hepatocellular Carcinoma  The New England Journal of Medicine

Tislelizumab vs Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma - The ...

Tislelizumab vs Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma  The ASCO Post

NRG/RTOG 1112: Radiotherapy Added to Sorafenib Improves Survival in Advanced Hepatocellular Carci...

NRG/RTOG 1112: Radiotherapy Added to Sorafenib Improves Survival in Advanced Hepatocellular Carcinoma  The ASCO Post

Impact of glucose metabolism on PD-L1 expression in sorafenib-resistant hepatocellular carcinoma ...

Impact of glucose metabolism on PD-L1 expression in sorafenib-resistant hepatocellular carcinoma cells  Nature

Durvalumab/Tremelimumab Improves Overall Survival vs Sorafenib in Patients With Advanced Hepatoce...

Durvalumab/Tremelimumab Improves Overall Survival vs Sorafenib in Patients With Advanced Hepatocellular Carcinoma HIMALAYA  The ASCO Post

USP29-mediated HIF1α stabilization is associated with Sorafenib resistance of hepatocellular carc...

USP29-mediated HIF1α stabilization is associated with Sorafenib resistance of hepatocellular carcinoma cells by upregulating glycolysis  Nature

Transcatheter arterial chemoembolization plus Sorafenib versus transcatheter arterial chemoemboli...

Transcatheter arterial chemoembolization plus Sorafenib versus transcatheter arterial chemoembolization plus Lenvatinib for intermediate hepatocellular carcinoma  Nature

The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular ca...

The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma  Nature

Ets1 mediates sorafenib resistance by regulating mitochondrial ROS pathway in hepatocellular carc...

Ets1 mediates sorafenib resistance by regulating mitochondrial ROS pathway in hepatocellular carcinoma  Nature

Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocell...

Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial  The Lancet

A comprehensive review of the relationship between autophagy and sorafenib-resistance in hepatoce...

A comprehensive review of the relationship between autophagy and sorafenib-resistance in hepatocellular carcinoma: ferroptosis is noteworthy  Frontiers

Knockdown of AKR1C3 Promoted Sorafenib Sensitivity Through Inhibiting the Phosphorylation of AKT ...

Knockdown of AKR1C3 Promoted Sorafenib Sensitivity Through Inhibiting the Phosphorylation of AKT in Hepatocellular Carcinoma  Frontiers

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma - NEJM Evidence

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma  NEJM Evidence

SBRT Prior to Sorafenib Improves Survival Over Sorafenib Alone in Advanced HCC - Oncology News Ce...

SBRT Prior to Sorafenib Improves Survival Over Sorafenib Alone in Advanced HCC  Oncology News Central

Tislelizumab Bests Sorafenib in Quality of Life in Unresectable HCC - Oncology News Central

Tislelizumab Bests Sorafenib in Quality of Life in Unresectable HCC  Oncology News Central

Effect of Spheroidal Age on Sorafenib Diffusivity and Toxicity in a 3D HepG2 Spheroid Model - Nature

Effect of Spheroidal Age on Sorafenib Diffusivity and Toxicity in a 3D HepG2 Spheroid Model  Nature

APOLLO Trial: OS Benefit with Anlotini Penpulimab in HCC - Oncodaily

APOLLO Trial: OS Benefit with Anlotini Penpulimab in HCC  Oncodaily

Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminar...

Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence  Nature

Arndt Vogel Highlights HEPATORCH Trial Results Comparing Toripalimab Plus Bevacizumab with Sorafe...

Arndt Vogel Highlights HEPATORCH Trial Results Comparing Toripalimab Plus Bevacizumab with Sorafenib in Advanced HCC  Oncodaily

Cabozantinib Is Safe and Tolerable in Sorafenib-Intolerant HCC - OncLive

Cabozantinib Is Safe and Tolerable in Sorafenib-Intolerant HCC  OncLive

Reversal of sorafenib resistance in hepatocellular carcinoma: epigenetically regulated disruption...

Reversal of sorafenib resistance in hepatocellular carcinoma: epigenetically regulated disruption of 14-3-3η/hypoxia-inducible factor-1α  Nature

RNA helicase DDX5 modulates sorafenib sensitivity in hepatocellular carcinoma via the Wnt/β-caten...

RNA helicase DDX5 modulates sorafenib sensitivity in hepatocellular carcinoma via the Wnt/β-catenin–ferroptosis axis  Nature

Phosphorylated FOXQ1, a novel substrate of JNK1, inhibits sorafenib-induced ferroptosis by activa...

Phosphorylated FOXQ1, a novel substrate of JNK1, inhibits sorafenib-induced ferroptosis by activating ETHE1 in hepatocellular carcinoma  Nature